Network controllability-based algorithm to target personalized driver genes for discovering combinatorial drugs of individual patients

Wei-Feng Guo,Shao-Wu Zhang,Yue-Hua Feng,Jing Liang,Tao Zeng,Luonan Chen
DOI: https://doi.org/10.1093/nar/gkaa1272
IF: 14.9
2021-01-12
Nucleic Acids Research
Abstract:Abstract Multiple driver genes in individual patient samples may cause resistance to individual drugs in precision medicine. However, current computational methods have not studied how to fill the gap between personalized driver gene identification and combinatorial drug discovery for individual patients. Here, we developed a novel structural network controllability-based personalized driver genes and combinatorial drug identification algorithm (CPGD), aiming to identify combinatorial drugs for an individual patient by targeting personalized driver genes from network controllability perspective. On two benchmark disease datasets (i.e. breast cancer and lung cancer datasets), performance of CPGD is superior to that of other state-of-the-art driver gene-focus methods in terms of discovery rate among prior-known clinical efficacious combinatorial drugs. Especially on breast cancer dataset, CPGD evaluated synergistic effect of pairwise drug combinations by measuring synergistic effect of their corresponding personalized driver gene modules, which are affected by a given targeting personalized driver gene set of drugs. The results showed that CPGD performs better than existing synergistic combinatorial strategies in identifying clinical efficacious paired combinatorial drugs. Furthermore, CPGD enhanced cancer subtyping by computationally providing personalized side effect signatures for individual patients. In addition, CPGD identified 90 drug combinations candidates from SARS-COV2 dataset as potential drug repurposing candidates for recently spreading COVID-19.
biochemistry & molecular biology
What problem does this paper attempt to address?
### Problems the Paper Attempts to Solve The paper aims to address the gap between personalized driver gene identification and combination drug discovery for individual patients in precision medicine. Specifically, the paper develops a personalized driver gene and combination drug identification algorithm based on structural network controllability (CPGD). Its goal is to identify personalized driver genes for individual patients from the perspective of network controllability and recommend combination drugs accordingly. #### Main Contributions: 1. **Personalized Driver Gene Identification**: Constructing personalized gene interaction networks (PGIN) by integrating somatic mutation data and personalized gene expression data. 2. **Combination Drug Prediction**: Using an improved network controllability method (weight-NCUA) to identify key personalized driver genes (PDGs) from PGIN, and subsequently predicting clinically effective combination drugs. 3. **Synergistic Effect Evaluation**: Evaluating the synergistic effects of combination drugs by assessing drug target-related information and the functional and chemical structure similarity of drugs. 4. **Cancer Subtype Enhancement**: Further distinguishing patients in different risk groups by quantifying the side effects of combination drugs on personalized driver genes. Experimental results on two benchmark datasets for breast cancer and lung cancer show that CPGD outperforms other state-of-the-art driver gene-focused methods in discovering known clinically effective combination drugs. Additionally, CPGD was applied to the SARS-CoV-2 dataset, identifying 90 potential drug combination candidates for treating COVID-19.